BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 25689254)

  • 1. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
    Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
    J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent H7 immunogens offer protection from H7N9 virus challenge.
    Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
    J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
    Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
    Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
    Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
    PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
    Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
    Henry Dunand CJ; Leon PE; Huang M; Choi A; Chromikova V; Ho IY; Tan GS; Cruz J; Hirsh A; Zheng NY; Mullarkey CE; Ennis FA; Terajima M; Treanor JJ; Topham DJ; Subbarao K; Palese P; Krammer F; Wilson PC
    Cell Host Microbe; 2016 Jun; 19(6):800-13. PubMed ID: 27281570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.
    Krammer F; Jul-Larsen A; Margine I; Hirsh A; Sjursen H; Zambon M; Cox RJ
    Clin Vaccine Immunol; 2014 Aug; 21(8):1153-63. PubMed ID: 24943383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
    Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
    Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
    Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
    Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
    Meseda CA; Atukorale V; Soto J; Eichelberger MC; Gao J; Wang W; Weiss CD; Weir JP
    Sci Rep; 2018 Mar; 8(1):5364. PubMed ID: 29599502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity between avian influenza A (H7N9) virus and divergent H7 subtypic- and heterosubtypic influenza A viruses.
    Guo L; Wang D; Zhou H; Wu C; Gao X; Xiao Y; Ren L; Paranhos-Baccalà G; Shu Y; Jin Q; Wang J
    Sci Rep; 2016 Feb; 6():22045. PubMed ID: 26907865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
    Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
    Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anamnestic broadly reactive antibodies induced by H7N9 virus more efficiently bind to seasonal H3N2 strains.
    Chen Y; Hilchey SP; Wang J; Garigen J; Zand MS; Huang J
    Hum Vaccin Immunother; 2022 Nov; 18(6):2128014. PubMed ID: 36197079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.
    Benjamin E; Wang W; McAuliffe JM; Palmer-Hill FJ; Kallewaard NL; Chen Z; Suzich JA; Blair WS; Jin H; Zhu Q
    J Virol; 2014 Jun; 88(12):6743-50. PubMed ID: 24696468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head.
    Jia M; Zhao H; Morano NC; Lu H; Lui YM; Du H; Becker JE; Yuen KY; Ho DD; Kwong PD; Shapiro L; To KK; Wu X
    Nat Commun; 2024 May; 15(1):4505. PubMed ID: 38802413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.